Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 156   

Articles published

MRK 56.47 +0.21 (0.37%)
price chart
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
No drug has hit the market running like Gilead Sciences' (NASDAQ: GILD ) freshly approved oral hepatitis C drug Sovaldi. In a market that analysts estimate could be worth up to $20 billion, Sovaldi's made a huge impact in gaining regulatory approval ...
Can Merck, Bristol-Myers, or AbbVie Compete with Gilead's Cure for ...  Wall St. Cheat Sheet
Drugmaker Studies Find a Bargain in $84000 Medicine  Bloomberg
Related articles »  
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences ...
While leader Gilead Sciences (NASDAQ: GILD ) waits on the FDA review for its combination of Sovaldi and levipasvir, and battles questions over Sovaldi's price tag, Merck is producing data on easy-to-treat populations and Bristol-Myers Squibb has turned ...
Related articles »  
Stocks to Watch Friday: Merck & Co., Inc., Deere & Company, and Toyota Motor ...
Momentum names that made notable moves on Thursday and could continue to do so into Friday's session include pharmaceutical firm Merck & Co., Inc. (NYSE:MRK), machinery concern Deere & Company (NYSE:DE), and automaker Toyota Motor Corp ...
Merck & Co. Price Target Increased to $70.00 by Analysts at MKM Partners ...  Ticker Report
Drug Most active stocks: Pfizer Inc. (NYSE:PFE), Merck & Co (NYSE:MRK ...  Gaining Green
Related articles »  
Brand Face-Off: GlaxoSmithKline plc (ADR) vs. Merck & Co., Inc.
Pharmaceutical giants GlaxoSmithKline plc (ADR) (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) have charted different paths during the last year.
Insider Selling: Merck & Co. Insider Unloads 145225 Shares of Stock (MRK)  Ticker Report
Related articles »  
Merck & Co., Inc. (NYSE:MRK) Reports Positives on its Hepatitis Treatment
Dallas, Texas 04/11/2014 (ustradevoice) - Merck & Co., Inc. (NYSE:MRK) continues to surge in the market after the company announced positive news, on the progress being made on the development of its hepatitis C combo therapies MK-5172 AND ...
Merck Hepatitis C combo pill impresses in Phase II  Seeking Alpha
Merck Data Show Potent Rival to Gilead's Hepatitis C Pill  Bloomberg
Related articles »  
Merck & Co., Inc. (NYSE:MRK)'s Oncology Break-Through MK-3475 Said To ...
It is the case with the breakthrough drug from Merck & Co., Inc. (NYSE:MRK) called the MK-3475 that provides efficient results in the treatment of non-small cell lung cancer (NSCLC).
Related articles »  
One Put, One Call Option To Know About For Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the May ...
Related articles »  
Merck & Co., Inc. (NYSE:MRK) Presents Immunotherapy Findings; Collaborates ...
Boston, MA 04/07/2014 (wallstreetpr) - Yesterday, Merck & Co., Inc. (NYSE:MRK) provided early discoveries associated with the relation between PD-L1 Expression and the clinical outcome of its under study Anti-PD-1 Immunotherapy, MK-3475 at AACR ...
Related articles »  
Stocks Buzz - Centene Corp (NYSE:CNC), Merck & Co., Inc (NYSE:MRK), Endo ...
Merck & Co., Inc (NYSE:MRK) recently declared interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C ...
Related articles »  
Which Of These Pharmaceutical Giants Has The Best Dividend: Pfizer Or Merck?
Before buying an interest in a publicly traded company, there are a number of things that you should think about. These things include the company's business model, valuation and future earnings growth. Another important consideration is the dividend.
DOW Healthcare Stocks in Consideration - Johnson & Johnson (NYSE:JNJ ...  eMarketsDaily
Related articles »